INTRODUCTION
============

Intracranial cerebral atherosclerosis (ICAS) is a major risk factor for cerebrovascular disease, particularly in Asians. ICAS is also associated with recurrent stroke, stroke-related morbidity, and future mortality.[@B1] The importance of ICAS for stroke patients and the associated factors and risk factors remain unclear, although they have been suggested to be aging, racial differences (mainly Asian), hypertension, diabetes mellitus, smoking, obstructive sleep apnea, and obesity.[@B2][@B3][@B4] Thus, further evaluations to find the factors that explain ICAS are necessary.

Fibroblast growth factor 23 (FGF23) is an endocrine FGF and phosphaturic hormone mainly formed by osteoblasts and osteocytes.[@B5] In harmony with Klotho (a single-pass transmembrane protein expressed in renal tubules), as an obligate coreceptor to bind and activate FGF receptors, FGF23 is activated during bone mineralization and turnover defects.[@B6] In addition, kidney dysfunction, adipose tissue inflammation, and vitamin D dysregulation are involved in systemic FGF23 regulation.[@B7] FGF23 is also involved in systemic atherosclerosis via nitric-oxide-associated endothelial dysfunction and calcium-phosphate-related bone mineralization.[@B8] Previous studies have found increased FGF23 to be associated with subclinical atherosclerosis and an increased left ventricular mass.[@B9][@B10][@B11] Furthermore, FGF23 is an independent predictor of cardiovascular events in the general population.[@B12]

Major features of ICAS include atherosis caused by cholesterol deposition and inflammation and sclerosis secondary to endothelial dysfunction, leading to arterial stiffness.[@B1] Because FGF23 is also involved in the development of atherosclerosis and endothelial dysfunction,[@B9][@B10][@B11][@B13] this growth factor might also be associated with the atherosclerosis of intracranial vessels. We hypothesized that a higher circulating FGF23 concentration is associated with the presence and burden of cerebral atherosclerosis in patients with acute ischemic stroke.

METHODS
=======

Subjects
--------

We prospectively registered 262 patients with first-ever ischemic stroke who were admitted to our institution between June 2014 and May 2016 within 7 days after symptom onset and had a stroke subtype classified as large-artery atherosclerosis, cardioembolism, or small-vessel occlusion. Standard protocols for the stroke registry were applied to all patients, which included a chest X-ray; 12-lead electrocardiography; routine blood tests at admission (white blood cell count, WBC) and creatinine) and after a 12-h fast {vitamin D \[25(OH)D\], fasting glucose, HbA1c, triglyceride, total cholesterol, low-density lipoprotein, total calcium, phosphate, albumin, alkaline phosphatase, uric acid, and CRP}; brain imaging with CT and/or MRI; and vascular imaging with CT angiography, magnetic resonance angiography (MRA), or digital subtraction angiography.[@B14][@B15] Patients who did not agree to participate in the study, refused to provide blood samples, or who had a history of cancer, autoimmune disease, or bone fractures during the previous 2 months were excluded.

Risk factors were defined as in a previous study and the Supplementary Materials (in the online-only Data Supplement).[@B16] The stroke subtype was classified using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification system.[@B17] Briefly, patients with potential cardiac emboli were classified as the cardioembolic subtype. If a patient exhibited substantial stenosis of the relevant artery, they were classified as the large-artery atherosclerosis subtype. The small-vessel occlusion subtype was defined if all of the following criteria were met: clinical manifestation of classical lacunar syndrome, relevant subcortical or brainstem lesion, infarction smaller than 15 mm, no significant stenosis in the relevant artery, and no potential cardiac embolism.[@B18] The Fazekas scoring system was used to assess white-matter hyperintensities (WMHs) in MRI FLAIR.[@B19] A Fazekas score of ≥2 in the periventricular or deep white matter was defined as high-grade WMH. The renal function was investigated using the estimated glomerular filtration rate according to the Modification of Diet in Renal Disease study equation.[@B20] This study was approved by our Institutional Review Board (approval no. ECT 2014-04-023), and we obtained informed consent from all participants and their next of kin.

MRI protocol and definition of vascular stenosis
------------------------------------------------

Every patient enrolled in this study underwent intracranial and extracranial MRA. All MR images were obtained using a 3.0-T imaging system (Magnetom Verio, Siemens Healthcare, Erlangen, Germany). Three-dimensional time-of-flight sequences were used to evaluate the intracranial arteries (intracranial internal carotid artery, middle cerebral artery, anterior cerebral artery, posterior cerebral artery, distal vertebral artery, and basilar artery) and the extracranial arteries (extracranial internal carotid artery and common carotid artery). Extracranial cerebral atherosclerosis (ECAS) was not assessed in the extracranial vertebral arteries because it is difficult to distinguish hypoplasia of the vertebral artery from significant stenosis.[@B3]

The method used in this study to evaluate stenosis has been described previously,[@B21] and \>50% stenosis was defined as ICAS.[@B22] ECAS was assessed using the criteria from the North American Symptomatic Carotid Endarterectomy Trial, with its presence defined as \>50% stenosis at the bifurcation of the bilateral carotid artery.[@B23] The most serious lesion was chosen when multiple stenotic lesions were present.[@B22][@B24] The total number of vessels with ICAS was considered as the ICAS burden (ranging from 0 to 11), while the total number of vessels with ECAS was considered the ECAS burden (ranging from 0 to 4).[@B24] Two neurologists blinded to clinical information (Y.C. and T.J.S.) independently assessed the presence of ICAS. The kappa value for interobserver agreement was 0.936 for the presence of ICAS. Any initial disagreements in the neurologist assessments of ICAS were resolved by discussion.

Measurement of plasma FGF23 concentrations
------------------------------------------

To measure the plasma FGF23 concentration, a blood sample were collected after a 12-h fast in EDTA tubes. The blood was centrifuged at 1,900×g and 4℃ for 15 min to obtain plasma, and then kept at −80℃ until being analyzed. The plasma FGF23 concentrations were measured using an ELISA with a commercial reagent (Kainos Laboratories, Tokyo, Japan).[@B25] The concentration detection range was 3--800 pg/mL, and so the assay was repeated using a 1/10 dilution for concentrations \>800 pg/mL.[@B25] The plasma FGF23 concentration was measured twice by two investigators blinded to the medical data (Y.C. and D.R.R.) and then averaged. Intra- and interassay coefficients of variability were 4.2% and 6.5%, respectively.

Statistical analysis
--------------------

Statistical analyses were conducted using the SPSS software package for Windows (version 21.0, IBM Corp., Armonk, NY, USA). Continuous variables were analyzed using the independent *t*-test, Mann-Whitney test, one-way ANOVA with Bonferroni\'s post-hoc analysis, and Kruskal-Wallis test. Categorical variables were analyzed using the chi-square or Fisher\'s exact test. Univariate and multivariate binary logistic regression analyses were performed to investigate the association between the plasma FGF23 concentration and cerebral atherosclerosis. To investigate the associations of age, body mass index, stroke severity, time to blood sampling from symptom onset, and blood laboratory findings with FGF23, Spearman correlation analysis was performed for the correlations between the National Institutes of Health Stroke Scale (NIHSS) score, blood laboratory findings, and FGF23 concentration.

The association between the plasma FGF23 concentration and the burden of cerebral atherosclerosis was investigated by performing a Spearman correlation analysis and univariate and multivariate ordinal logistic regression analyses. Ordinal logistic regression was used to analyze the association between the FGF23 concentration and the number of arteries with cerebral atherosclerosis. The odds ratio (OR) in ordinal regression expresses the common odds for the increase in the number of arteries with cerebral atherosclerosis at each count. Sex, age, and variables for which *p*\<0.1 in the univariate analysis were included in the multivariate logistic regression. In the multivariate analysis, sex, age, body mass index, coronary artery disease, prestroke antithrombotics, stroke subtype, NIHSS score, high-grade WMHs, Klotho, triglyceride, WBC count, total calcium, and C-reactive protein were adjusted for the presence and burden of ICAS; sex, age, hypertension, stroke subtype, NIHSS score, high-grade WMHs, WBC count, phosphate, and uric acid were adjusted for the presence and burden of ECAS; and sex, age, hypertension, prestroke antithrombotics, NIHSS score, high-grade WMHs, Klotho, triglyceride, WBC count, and C-reactive protein were adjusted for the presence and burden of both ICAS and ECAS. For sensitivity analysis, we investigated the presence of statistical interactions according to underlying renal dysfunction (\<60 mL/min/1.73 m^2^), which was closely related to the plasma FGF23 concentration.[@B11] A two-tailed probability value of *p*\<0.05 was considered statistically significant.

RESULTS
=======

Demographic data and comparative analysis according to presence of cerebral atherosclerosis
-------------------------------------------------------------------------------------------

[Fig. 1](#F1){ref-type="fig"} shows a flowchart of participants according to the inclusion and exclusion criteria applied in this study. The demographics and accompanying risk factors and prior stroke medications did not differ significantly between the included and excluded patients ([Supplementary Table 1](#S1){ref-type="supplementary-material"} in the online-only Data Supplement). [Table 1](#T1){ref-type="table"} lists the demographics of the patients in our study. The 262 patients included 58.0% (*n*=152) males. The mean age was 64.7 years, and the plasma FGF23 concentration was 347.5±549.6 pg/mL (mean±SD). The most common stroke subtype was large-artery atherosclerosis (41.2%, *n*=108), followed by small-vessel occlusion (40.8%, *n*=107) and cardioembolism (17.9%, *n*=47). The plasma FGF23 concentration did not differ among stroke subtypes (*p*=0.174). ICAS only, ECAS only, and both ICAS and ECAS were present in 31.2% (*n*=82), 4.9% (*n*=13), and 6.8% (*n*=18) of the subjects, respectively ([Table 1](#T1){ref-type="table"}). The patients with ICAS and both ICAS and ECAS were older (*p*=0.002) and had higher NIHSS scores (*p*=0.002) than those without cerebral atherosclerosis. Moreover, patients with ICAS only, ECAS only, or both ICAS and ECAS more often had a history of hypertension (*p*=0.003) and large-artery atherosclerosis stroke subtype (*p*=0.001).

The blood laboratory findings indicated that the plasma FGF23 concentration (*p*=0.001), WBC count (*p*=0.014), and C-reactive protein concentration (*p*=0.017) were higher in patients with both ICAS and ECAS than in patients without cerebral atherosclerosis. Patients with ICAS had higher plasma concentrations of FGF23 (*p*=0.037) and C-reactive protein (*p*=0.043) compared with patients without cerebral atherosclerosis. Patients with both ICAS and ECAS had a higher plasma FGF23 concentration compared with patients with only ICAS (*p*=0.001) or only ECAS (*p*=0.001) ([Table 1](#T1){ref-type="table"}).

The plasma FGF23 concentration was positively correlated with age (ρ=0.150, *p*=0.015), NIHSS score (ρ=0.198, *p*=0.001), vitamin D \[25(OH)D\] concentration (ρ=0.143, *p*=0.020), HbA1c (ρ=0.162, *p*=0.008), triglyceride concentration (ρ=0.319, *p*\<0.001), WBC count (ρ=0.130, *p*=0.035), and creatinine (ρ=0.178, *p*=0.004), total calcium (ρ=0.153, *p*=0.043), phosphate (ρ=0.148, *p*=0.048), and C-reactive protein (ρ=0.134, *p*=0.030) concentrations. Moreover, the plasma FGF23 concentration was negatively correlated with the Klotho concentration (ρ=−0.325, *p*\<0.001).

Association of FGF23 with presence of cerebral atherosclerosis
--------------------------------------------------------------

In a multivariate binary logistic analysis, the plasma FGF23 concentration was positively correlated with the presence of ICAS even after adjustment as a continuous variable (per 100 pg/mL) (OR=1.07, 95% CI=1.00--1.15, *p*=0.039) or dichotomizing based on the median value (cutoff value=182.0 pg/mL; OR=2.52, 95% CI=1.36--4.68, *p*=0.003) and tertiles \[comparing the upper tertile (≥235.16 pg/mL) with the lower tertile (0--146.79 pg/mL): OR=3.28, 95% CI=1.53--7.05\] ([Table 2](#T2){ref-type="table"}, [Supplementary Table 2](#S2){ref-type="supplementary-material"} in the online-only Data Supplement). The plasma FGF23 concentration was marginally related to the presence of ECAS after adjustment as a continuous variable (per 100 pg/mL; OR=1.05, 95% CI=0.99--1.12, *p*=0.073), but it was not associated with the presence of ECAS after adjustment using the median cutoff value or tertiles ([Table 2](#T2){ref-type="table"}, [Supplementary Table 2](#S2){ref-type="supplementary-material"} in the online-only Data Supplement). The plasma FGF23 concentration was significantly and positively correlated with the presence of both ICAS and ECAS after adjustment as a continuous variable (per 100 pg/mL; OR=1.10, 95% CI=1.02--1.19, *p*=0.013) ([Table 2](#T2){ref-type="table"}, [Supplementary Table 2](#S2){ref-type="supplementary-material"} in the online-only Data Supplement).

There was no statistical interaction between the presence of ICAS (*p* for interaction=0.872) and ECAS (*p* for interaction=0.764) with the presence of renal dysfunction (\<60 mL/min/1.73 m^2^).

Association of FGF23 with the burden of cerebral atherosclerosis
----------------------------------------------------------------

The plasma FGF23 concentration was associated with the ICAS burden (ρ=0.317, *p*=0.001) and the ECAS burden (ρ=0.145, *p*=0.019). The association of FGF23 with the burden of cerebral atherosclerosis is presented as [Fig. 2](#F2){ref-type="fig"}. In a multivariate ordinal logistic analysis, the plasma FGF23 concentration was positively correlated with the burden of ICAS even after adjustment as a continuous variable (per 100 pg/mL; OR=1.09, 95% CI=1.04--1.15, *p*=0.001) or dichotomizing based on the median value (cutoff value=182.0 pg/mL; OR=1.10, 95% CI=1.58--5.06, *p*=0.001) and tertiles \[comparing the upper tertile (≥235.16 pg/mL) with the lower tertile (0--146.79 pg/mL): OR=3.30, 95% CI=1.60--6.75\] ([Table 2](#T2){ref-type="table"}, [Supplementary Table 3](#S3){ref-type="supplementary-material"} in the online-only Data Supplement). The plasma FGF23 concentration was related to the burden of ECAS after adjustment as a continuous variable (per 100 pg/mL; OR=1.06, 95% CI=1.00--1.12, *p*=0.038) but not after adjustment using the median cutoff value or tertiles ([Table 2](#T2){ref-type="table"}, [Supplementary Table 3](#S3){ref-type="supplementary-material"} in the online-only Data Supplement). The plasma FGF23 concentration was significantly and positively correlated with the burden of both ICAS and ECAS after adjustment as a continuous variable (per 100 pg/mL; OR=1.10, 95% CI=1.02--1.19, *p*=0.013) ([Table 2](#T2){ref-type="table"}, [Supplementary Table 3](#S3){ref-type="supplementary-material"} in the online-only Data Supplement).

DISCUSSION
==========

The key finding of our study is that a higher plasma FGF23 concentration was associated with the presence and burden of cerebral atherosclerosis, particularly for ICAS. An association of FGF23 with cerebral atherosclerosis has rarely been reported. A community-based study found that a higher circulating FGF23 concentration was associated with systemic atherosclerosis.[@B26] Moreover, a higher FGF23 concentration was found to be a risk factor for chronic kidney diseases, especially in older, disabled, community-dwelling females.[@B27] In patients with chronic kidney diseases, an elevated FGF23 concentration reportedly contributes directly to a higher rate of left ventricular hypertrophy[@B28] and a higher coronary artery disease burden.[@B29] Combined with previous research, the present study is significant because it confirms the association between the plasma FGF23 concentration and the presence and burden of cerebral atherosclerosis, specifically in stroke patients.

While our study cannot suggest the exact mechanism linking plasma FGF23 and cerebral atherosclerosis, there are plausible hypotheses. First, vascular inflammation of cerebral arteries may explain the relationship between FGF23 and cerebral atherosclerosis. Previous studies have found FGF23 to be an important mediator of vessel inflammation that preceded arteriolosclerosis or arterial stiffness, which was the main cause of cerebral atherosclerosis development, particularly for ICAS.[@B22][@B30] Moreover, FGF23 stimulates the hepatic secretion of the inflammatory markers IL-6 and C-reactive protein.[@B30] C-reactive protein is a sensitive indicator of vascular inflammation and a marker of cerebral atherosclerosis.[@B31] In line with these previous results, the present study found that the plasma FGF23 concentration was positively correlated with that of C-reactive protein, with the latter also being higher in patients with accompanying ICAS than in those without cerebral atherosclerosis. Second, FGF23 is a phosphaturic hormone produced mainly by osteoblasts and osteocytes, and is implicated in blood calcium and phosphate concentrations, the vitamin D pathway, and ectopic site mineralization.[@B5] Increased FGF23 activity disturbs the calcitriol-calcium/phosphate regulation pathway, which may cause hypercalcemia and hyperphosphatemia, likely accounting for the association with ectopic site mineralization.[@B32][@B33] Previous studies have demonstrated the serum calcium concentration to be positively correlated with the presence of ICAS; in contrast, the serum phosphate concentration was not associated with ICAS.[@B34] Furthermore, the phosphate concentration was positively correlated with a greater prevalence of vascular calcification, which is frequently associated with ECAS.[@B35][@B36] Therefore, an FGF23-related calcium-phosphate regulation mechanism may affect the development of cerebral atherosclerosis. Actually, the present study found that the plasma FGF23 was positively correlated with serum calcium and phosphate concentrations, and also that the serum calcium and phosphate concentrations were related to the presence and burden of ICAS and ECAS, respectively.

This study found that the presence and burden of ICAS were significantly associated with a higher FGF23 concentration, whereas the presence and burden of ECAS were not, even though they were related in a univariate analysis. These results may have been due to the sample being too small to reveal a relationship between FGF23 and ECAS. Moreover, other confounding factors such as hypertension are more strongly associated with ECAS than with the FGF23 concentration. In addition, arterial stiffness may be associated with ICAS (rather than ECAS) in Asians,[@B22] and arterial stiffness is also closely related to FGF23,[@B37] which may explain our results. Our study also suggests the presence of a pathophysiological association between circulating FGF23 and ICAS.

This study was subject to some limitations. We did not measure the plasma FGF23 concentration in the general population. However, the main goals of our study were to determine any associations with the presence and burden of cerebral atherosclerosis in stroke patients. All blood samples and brain imaging findings in this study were acquired from acute stroke patients at the time of admission, and so serial changes in the FGF23 concentration and the association of FGF23 with the long-term progression of cerebral atherosclerosis could not be investigated. Although our study prospectively enrolled ischemic stroke patients, it is difficult to generalize our findings and selection bias might have been present due to the smallness of the sample and the exclusion of undetermined stroke subtypes. Even though the plasma FGF23 concentration was found to be associated with the presence of ICAS and ECAS, it did not differ among stroke subtypes. This may have been due to the cardioembolic stroke mechanism or the sample smallness reducing the statistical power. Finally, we did not measure thyroid and parathyroid hormones that may affect the FGF23 concentration, or examine bone abnormalities in the enrolled patients.

In conclusion, this study has demonstrated that a higher plasma FGF23 concentration is independently associated with the presence and burden of cerebral atherosclerosis, particularly with ICAS in stroke patients. We attribute these associations to the essential role of FGF23 in cerebral atherosclerosis.
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=======================

The online-only Data Supplement is available with this article at <https://doi.org/10.3988/jcn.2020.16.1.29>.

###### Supplementary Table 1

Comparison for demographic data of subjects who included and excluded for this study

###### Supplementary Table 2

Multivariate analysis for the presence of cerebral atherosclerosis

###### Supplementary Table 3

Multivariate analysis for the burden of cerebral atherosclerosis

![Flowchart of participants according to inclusion and exclusion criteria.](jcn-16-29-g001){#F1}

![Association of FGF23 with the burden of ICAS (A) and the burden of ECAS (B). X-axis indicates the burden of each type of cerebral atherosclerosis, and Y-axis indicates the value of natural logarithm of FGF23. ECAS: extracranial cerebral atherosclerosis, FGF23: fibroblast growth factor 23, ICAS: intracranial cerebral atherosclerosis.](jcn-16-29-g002){#F2}

###### Comparison of clinical characteristics and blood laboratory findings according the presence of cerebral atherosclerosis

![](jcn-16-29-i001)

                                                 Total (*n*=262)      No cerebral atherosclerosis (*n*=149)   ECAS only (*n*=13)   ICAS only (*n*=82)   Both ECAS and ICAS (*n*=18)   *p*
  ---------------------------------------------- -------------------- --------------------------------------- -------------------- -------------------- ----------------------------- -------
  Demographics                                                                                                                                                                        
   Sex, male                                     152 (58.0)           89 (59.7)                               10 (76.9)            43 (52.4)            10 (55.6)                     0.365
   Age, years                                    64.7±12.3            62.4±12.0                               64.6±13.9            67.5±12.3^\*^        71.5±8.5^\*^                  0.002
   Body mass index, kg/m^2^                      24.0±3.3             23.7±2.8                                23.0±2.2             24.6±4.1             24.3±3.9                      0.186
  Risk factors                                                                                                                                                                        
   Hypertension                                  153 (58.4)           77 (51.7)                               10 (76.9)            49 (59.8)            17 (94.4)                     0.003
   Diabetes mellitus                             108 (41.2)           56 (37.6)                               5 (38.5)             38 (46.3)            9 (50.0)                      0.510
   Hypercholesterolemia                          74 (28.2)            40 (26.8)                               2 (15.4)             27 (32.9)            5 (27.8)                      0.553
   Coronary artery disease                       47 (17.9)            22 (14.8)                               2 (15.4)             17 (20.7)            6 (33.3)                      0.221
   Smoking                                       98 (37.4)            56 (37.6)                               5 (38.5)             31 (37.8)            6 (33.3)                      0.986
   Alcohol intake                                73 (27.9)            48 (32.2)                               4 (30.8)             17 (20.7)            4 (22.2)                      0.282
  Prior medication                                                                                                                                                                    
   Antithrombotics                               55 (21.0)            24 (16.1)                               2 (15.4)             21 (25.6)            8 (44.4)                      0.024
   Statins                                       53 (20.2)            32 (21.5)                               4 (30.8)             13 (15.9)            4 (22.2)                      0.561
  Stroke subtype                                                                                                                                                                      0.001
   Small-vessel occlusion                        107 (40.8)           85 (57.0)                               2 (15.4)             16 (19.5)            4 (22.2)                      
   Large-artery atherosclerosis                  108 (41.2)           37 (24.8)                               9 (69.2)             51 (62.2)            11 (61.1)                     
   Cardioembolism                                47 (17.9)            27 (18.1)                               2 (15.4)             15 (18.3)            3 (16.7)                      
  NIHSS score                                    3 \[2--6\]           3 \[2--5\]                              2 \[1--8\]           5 \[2--8\]^\*^       6 \[3--12\]^\*^               0.002
  High-grade WMHs                                64 (24.4)            30 (20.1)                               4 (30.8)             22 (26.8)            8 (44.4)                      0.115
  Time to blood sampling from symptom onset, h   11.3 \[4.6--20.4\]   11.8 \[5.0--21.1\]                      11.1 \[4.1--19.8\]   11.0 \[4.2--19.6\]   11.2 \[4.4--20.6\]            0.218
  Blood laboratory findings                                                                                                                                                           
   FGF23, pg/mL                                  347.5±549.6          255.9±348.3                             153.0±71.7           394.4±617.4^\*^      1033.0±1073.1^\*†‡^           0.001
   Klotho, pg/mL                                 312.7±153.3          327.0±140.4                             382.1±253.4          285.1±142.2          270.1±190.8                   0.045
   Vitamin D \[25(OH)D\], ng/mL                  20.1±6.8             19.9±7.0                                17.9±6.6             21.1±6.7             19.7±5.4                      0.350
   HbA1c, %                                      6.5±1.4              6.4±1.3                                 6.9±1.7              6.7±1.5              6.4±1.1                       0.224
   Triglyceride, mg/dL                           129.0±95.6           121.8±90.3                              101.3±37.2           141.7±114.0          150.6±63.6                    0.233
   Low-density lipoprotein, mg/dL                115.0±36.9           112.2±35.4                              111.6±49.7           118.5±37.9           124.6±33.9                    0.401
   White blood cell count, ×10^3^                7.3±2.4              7.1±2.1                                 7.9±3.7              7.4±2.4              9.0±2.7^\*^                   0.014
   Creatinine, mg/dL                             1.0±0.8              1.0±0.9                                 0.9±0.1              0.9±0.3              1.3±1.5                       0.182
   Total calcium, mg/dL                          8.2±0.4              8.2±0.4                                 8.2±0.4              8.3±0.4              8.3±0.6                       0.375
   Phosphate, mg/dL                              3.1±0.6              3.1±0.5                                 3.3±0.6              3.1±0.5              3.5±1.0                       0.083
   Alkaline phosphatase, IU/L                    224.4±72.2           225.1±70.4                              209.0±45.1           227.8±81.6           213.7±58.0                    0.761
   Uric acid, mg/dL                              4.8±1.6              4.8±1.5                                 5.5±1.9              4.6±1.5              5.2±2.1                       0.288
   CRP, mg/L                                     0.9±2.8              0.5±1.3                                 0.7±1.1              1.5±1.3^\*^          2.2±3.2^\*^                   0.017

Data are *n* (%), mean±SD, or median \[interquartile range\] values.

^\*^*p*\<0.05 compared with no cerebral atherosclerosis in a Bonferroni post-hoc analysis, ^†^*p*\<0.05 compared with ECAS only in a Bonferroni post-hoc analysis, ^‡^*p*\<0.05 compared with ICAS only in a Bonferroni post-hoc analysis.

ECAS: extracranial cerebral atherosclerosis, FGF23: fibroblast growth factor 23, ICAS: intracranial cerebral atherosclerosis, NIHSS: National Institute of Health Stroke Scale, WMHs: white-matter hyperintensities.

###### Results of multivariate analyses of the presence and burden of cerebral atherosclerosis

![](jcn-16-29-i002)

  FGF23                                               Presence of cerebral atherosclerosis                                                           
  --------------------------------------------------- -------------------------------------- ------- ------------------- ------- ------------------- -------
  Continuous variable, per 100 pg/mL                  1.07 (1.00--1.15)                      0.039   1.05 (0.99--1.12)   0.073   1.10 (1.02--1.19)   0.013
  Dichotomized based on median value of 182.0 pg/mL   2.52 (1.36--4.68)                      0.003   1.59 (0.66--3.87)   0.248   Not available^\*^   
  Tertiles                                                                                                                                           
   Lower tertile, 0--146.79 pg/mL                     Reference                                      Reference                   Reference           
   Middle tertile, 146.79--235.16 pg/mL               1.96 (0.93--4.12)                      0.076   1.97 (0.64--6.08)   0.482   Not available^\*^   
   Upper tertile, ≥235.16 pg/mL                       3.28 (1.53--7.05)                      0.002   1.26 (0.42--3.75)   0.523   Not available^\*^   

  FGF23                                               Burden of cerebral atherosclerosis                                                           
  --------------------------------------------------- ------------------------------------ ------- ------------------- ------- ------------------- -------
  Continuous variable, per 100 pg/mL                  1.09 (1.04--1.15)                    0.001   1.06 (1.00--1.12)   0.038   1.10 (1.02--1.19)   0.013
  Dichotomized based on median value of 182.0 pg/mL   1.10 (1.58--5.06)                    0.001   1.63 (0.66--3.99)   0.283   Not available^\*^   
  Tertiles                                                                                                                                         
   Lower tertile, 0--146.79 pg/mL                     Reference                                    Reference                   Reference           
   Middle tertile, 146.79--235.16 pg/mL               2.27 (1.10--4.67)                    0.001   1.35 (0.44--4.11)   0.590   Not available^\*^   
   Upper tertile, ≥235.16 pg/mL                       3.30 (1.60--6.75)                    0.026   2.09 (0.66--6.53)   0.204   Not available^\*^   

Data are odds ratio (95% CI) values.

^\*^Odds ratio could not be obtained because the FGF23 concentrations of patients with both ECAS and ICAS exceeded 182.0 pg/mL, ^†^Adjusted for sex, age, BMI, coronary artery disease, prestroke antithrombotics, stroke subtype, NIHSS score, high-grade WMHs, Klotho, triglyceride, WBC count, total calcium, and CRP, ^‡^Adjusted for sex, age, hypertension, stroke subtype, NIHSS score, high-grade WMHs, WBC count, phosphate, and uric acid, ^§^Adjusted for sex, age, hypertension, prestroke antithrombotics, NIHSS score, high-grade WMHs, Klotho, triglyceride, WBC count, and CRP.

BMI: body mass index, ECAS: extracranial cerebral atherosclerosis, FGF23: fibroblast growth factor 23, ICAS: intracranial cerebral atherosclerosis, NIHSS: National Institutes of Health Stroke Scale, WBC: white blood cell, WMHs: white-matter hyperintensities.

[^1]: ^\*^These authors contributed equally to this work.
